A study for the difference in effects of high-dose prednisolone therapy for autoimmune disease patients

A study for the difference in effects of high-dose prednisolone therapy for autoimmune disease patients - A study for the difference in effects of high-dose prednisolone therapy for autoimmune disease patients

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000007673

Enrollment

100

Registered

2012-04-05

Start date

2012-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatic disease like dermatomyositis, polymyositis, systemic lupus erythematosus, vasculitides, adult Still&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Rheumatic disease patients who receive oral high-dose (more than 0.8mg/kg/day) prednisolone monotherapy

Exclusion criteria

Exclusion criteria: Patients who have taken oral prednisolone for long time Patients who have allergy to prednisolone

Design outcomes

Primary

Measure	Time frame
Improvement of the Disease activity of rheumatic diseases 2 weeks after the induction of oral prednisolone therapy	—

Countries

Japan

Outcome results